Caplyta (lumateperone)
Effective 02/01/2021

<table>
<tr><td>Plan</td><td>☒ MassHealth
☐Commercial/Exchange</td><td rowspan="2">Program Type</td><td rowspan="2">☒ Prior Authorization
☒ Quantity Limit
☐ Step Therapy</td></tr>
<tr><td>Benefit</td><td>☒ Pharmacy Benefit
☐ Medical Benefit (NLX)</td></tr>
<tr><td>Specialty Limitations</td><td colspan="3">N/A</td></tr>
<tr><td rowspan="8">Contact Information</td><td colspan="3">Specialty Medications</td></tr>
<tr><td>All Plans</td><td>Phone: 866-814-5506</td><td>Fax: 866-249-6155</td></tr>
<tr><td colspan="3">Non-Specialty Medications</td></tr>
<tr><td>MassHealth</td><td>Phone: 877-433-7643</td><td>Fax: 866-255-7569</td></tr>
<tr><td>Commercial</td><td>Phone: 800-294-5979</td><td>Fax: 888-836-0730</td></tr>
<tr><td>Exchange</td><td>Phone: 855-582-2022</td><td>Fax: 855-245-2134</td></tr>
<tr><td colspan="3">Medical Specialty Medications (NLX)</td></tr>
<tr><td>All Plans</td><td>Phone: 844-345-2803</td><td>Fax: 844-851-0882</td></tr>
<tr><td>Exceptions</td><td colspan="3">N/A</td></tr>
</table>

Overview
Caplyta (lumateperone) is a second-generation antipsychotic with antagonist activity at central serotonin 5-HT_{2A} receptors and postsynaptic antagonist activity at central dopamine D_2 receptors. Caplyta is approved for treatment of adults with schizophrenia.

Coverage Guidelines
Authorization may be granted for members when all the following criteria are met, and documentation is provided for the following drug and/or diagnosis specific criteria:

Members ≥ 18 years of age:
1. The member has a diagnosis of schizophrenia
2. The member has had inadequate response, adverse reaction, or contraindication to TWO (2) second-generation (atypical) antipsychotic (generic or brand)

Members < 18 years of age:
1. The member has a diagnosis of schizophrenia
2. **ONE** of the following:
    a. Inadequate response or adverse reaction ONE (1) of the following second-generation (atypical) antipsychotics: aripiprazole, clozapine, olanzapine, quetiapine, risperidone, or ziprasidone
    b. Contraindication to ALL second-generation (atypical) antipsychotics
3. **ONE** of the following:
    a. Inadequate response or adverse reaction to TWO (2) other different atypical or typical antipsychotics
    b. Contraindication to ALL antipsychotics

Continuation of Therapy
Reauthorization requires physician attestation of continuation of therapy.

Limitations

1. Initial approvals and reauthorizations will be granted for 12 months
2. The following quantity limits apply:

Caplyta 42mg	30 tablets per 30 days

References

1. Caplyta (lumateperone) [prescribing information]. New York, NY: Intra-Cellular Therapies Inc; December 2019.

Review History

01/20/2021 – Created and Reviewed January P&T Mtg; matched MH criteria. Effective 02/01/21.

Disclaimer

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.